Abstract
Duloxetine is a selective serotonin–noradrenaline reuptake inhibitor approved for treatment of major depressive disorder. So far, duloxetine has been found to be well tolerated and reported cardiac side effects were negligible. However, pharmacological effects on cardiac hERG channels have not been properly addressed yet. hERG channels were expressed in Xenopus oocytes and a human embryonic kidney (HEK) cell line. Currents were measured using voltage clamp and patch clamp techniques. Channel surface expression was quantified using Western blot analysis. We found that duloxetine inhibits heterologously expressed hERG channels in a concentration-dependent manner, yielding an IC50 of 142.8 μM in Xenopus oocytes. Inhibitory effects were even more pronounced when using a mammalian cell line resulting in a 34 or 59 % current decrease by 10 or 30 μM duloxetine, respectively. Duloxetine did not affect channel activation or inactivation kinetics. However, channel deactivation was accelerated by duloxetine. We further showed that inhibition occurs in the open and inactivated, but not closed, states. There was no frequency dependence of block. However, effects of duloxetine were significantly attenuated when using the hERG pore mutants Y652A and F656A. Subacute effects of duloxetine on hERG channel expression were analyzed using the Western blot technique. We found that incubation with duloxetine results in a concentration-dependent decrease of channel surface expression. Whereas inhibitory effects of duloxetine seem negligible under therapeutically relevant concentrations, hERG block should be considered in cases of duloxetine overdose and when administering duloxetine to patients susceptible to drug-induced QT prolongation.
Similar content being viewed by others
References
Choi J-S, Hahn SJ (2012) Duloxetine blocks cloned Kv4.3 potassium channels. Brain Res 1466:15–23. doi:10.1016/j.brainres.2012.05.028
Curran ME, Splawski I, Timothy KW et al (1995) A molecular basis for cardiac arrhythmia: HERG mutations cause long QT syndrome. Cell 80:795–803
Dennis A, Wang L, Wan X, Ficker E (2007) hERG channel trafficking: novel targets in drug-induced long QT syndrome. Biochem Soc Trans 35:1060–1063. doi:10.1042/BST0351060
Derby MA, Zhang L, Chappell JC et al (2007) The effects of supratherapeutic doses of duloxetine on blood pressure and pulse rate. J Cardiovasc Pharmacol 49:384–393. doi:10.1097/FJC.0b013e31804d1cce
Ficker E, Kuryshev YA, Dennis AT et al (2004) Mechanisms of arsenic-induced prolongation of cardiac repolarization. Mol Pharmacol 66:33–44. doi:10.1124/mol.66.1.33
Goldstein DJ (2007) Duloxetine in the treatment of major depressive disorder. Neuropsychiatr Dis Treat 3:193–209
Kiehn J, Lacerda AE, Brown AM (1999) Pathways of HERG inactivation. Am J Physiol 277:H199–210
Kobayashi T, Washiyama K, Ikeda K (2011) Inhibition of G protein-activated inwardly rectifying K+ channels by different classes of antidepressants. PLoS One 6:e28208. doi:10.1371/journal.pone.0028208
Kuryshev YA, Ficker E, Wang L et al (2005) Pentamidine-induced long QT syndrome and block of hERG trafficking. J Pharmacol Exp Ther 312:316–323. doi:10.1124/jpet.104.073692
Lantz RJ, Gillespie TA, Rash TJ et al (2003) Metabolism, excretion, and pharmacokinetics of duloxetine in healthy human subjects. Drug Metab Dispos 31:1142–1150. doi:10.1124/dmd.31.9.1142
Mitcheson JS, Chen J, Lin M et al (2000) A structural basis for drug-induced long QT syndrome. Proc Natl Acad Sci USA 97:12329–12333. doi:10.1073/pnas.210244497
Priori SG, Napolitano C (2002) Genetic defects of cardiac ion channels. The hidden substrate for torsades de pointes. Cardiovasc Drugs Ther 16:89–92
Rajamani S, Eckhardt LL, Valdivia CR et al (2006) Drug-induced long QT syndrome: hERG K+ channel block and disruption of protein trafficking by fluoxetine and norfluoxetine. Br J Pharmacol 149:481–489. doi:10.1038/sj.bjp.0706892
Redfern WS, Carlsson L, Davis AS et al (2003) Relationships between preclinical cardiac electrophysiology, clinical QT interval prolongation and torsade de pointes for a broad range of drugs: evidence for a provisional safety margin in drug development. Cardiovasc Res 58:32–45
Roden DM, Balser JR, George AL, Anderson ME (2002) Cardiac ion channels. Annu Rev Physiol 64:431–475. doi:10.1146/annurev.physiol.64.083101.145105
Sanguinetti MC (2010) HERG1 channelopathies. Pflugers Arch 460:265–276. doi:10.1007/s00424-009-0758-8
Sanguinetti MC, Jiang C, Curran ME, Keating MT (1995) A mechanistic link between an inherited and an acquired cardiac arrhythmia: HERG encodes the I Kr potassium channel. Cell 81:299–307
Scherer D, Hassel D, Bloehs R et al (2009) Selective noradrenaline reuptake inhibitor atomoxetine directly blocks hERG currents. Br J Pharmacol 156:226–236. doi:10.1111/j.1476-5381.2008.00018.x
Scholz EP, Zitron E, Kiesecker C et al (2003) Drug binding to aromatic residues in the HERG channel pore cavity as possible explanation for acquired long QT syndrome by antiparkinsonian drug budipine. Naunyn Schmiedebergs Arch Pharmacol 368:404–414. doi:10.1007/s00210-003-0805-5
Scholz EP, Zitron E, Kiesecker C et al (2005) Inhibition of cardiac HERG channels by grapefruit flavonoid naringenin: implications for the influence of dietary compounds on cardiac repolarisation. Naunyn Schmiedebergs Arch Pharmacol 371:516–525. doi:10.1007/s00210-005-1069-z
Scholz EP, Konrad FM, Weiss DL et al (2007) Anticholinergic antiparkinson drug orphenadrine inhibits HERG channels: block attenuation by mutations of the pore residues Y652 or F656. Naunyn Schmiedebergs Arch Pharmacol 376:275–284. doi:10.1007/s00210-007-0202-6
Scholz EP, Niemer N, Hassel D et al (2009) Biophysical properties of zebrafish ether-à-go-go related gene potassium channels. Biochem Biophys Res Commun 381:159–164. doi:10.1016/j.bbrc.2009.02.042
Sharma A, Goldberg MJ, Cerimele BJ (2000) Pharmacokinetics and safety of duloxetine, a dual-serotonin and norepinephrine reuptake inhibitor. J Clin Pharmacol 40:161–167
Thase ME, Tran PV, Wiltse C et al (2005) Cardiovascular profile of duloxetine, a dual reuptake inhibitor of serotonin and norepinephrine. J Clin Psychopharmacol 25:132–140
Vandenberg JI, Varghese A, Lu Y et al (2006) Temperature dependence of human ether-a-go-go-related gene K+ currents. Am J Physiol, Cell Physiol 291:C165–75. doi:10.1152/ajpcell.00596.2005
Wang S-Y, Calderon J, Kuo Wang G (2010) Block of neuronal Na+ channels by antidepressant duloxetine in a state-dependent manner. Anesthesiology 113:655–665. doi:10.1097/ALN.0b013e3181e89a93
Wenzel-Seifert K, Wittmann M, Haen E (2011) QTc prolongation by psychotropic drugs and the risk of Torsade de Pointes. Dtsch Arztebl Int 108:687–693. doi:10.3238/arztebl.2011.0687
Wong DT, Bymaster FP, Mayle DA et al (1993) LY248686, a new inhibitor of serotonin and norepinephrine uptake. Neuropsychopharmacology 8:23–33
Xue F, Strombom I, Turnbull B et al (2012) Treatment with duloxetine in adults and the incidence of cardiovascular events. J Clin Psychopharmacol 32:23–30. doi:10.1097/JCP.0b013e31823fb238
Zhang L, Chappell J, Gonzales CR et al (2007) QT effects of duloxetine at supratherapeutic doses: a placebo and positive controlled study. J Cardiovasc Pharmacol 49:146–153. doi:10.1097/FJC.0b013e318030aff7
Acknowledgments
This work was supported by grants from the German Research Foundation (DFG), Zi1177/1-1, Scho1350/1-1, and Scho1350/2-1 (to E.Z. and E.P.S.). F.F. is supported by the Hartmut Hoffmann-Berling International Graduate School of Molecular and Cellular Biology. The skilful assistance of Christine Jeckel is gratefully acknowledged.
Conflict of interest
None.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Fischer, F., Vonderlin, N., Seyler, C. et al. Acute and subacute effects of the selective serotonin–noradrenaline reuptake inhibitor duloxetine on cardiac hERG channels. Naunyn-Schmiedeberg's Arch Pharmacol 386, 795–804 (2013). https://doi.org/10.1007/s00210-013-0878-8
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00210-013-0878-8